They've been pretty clear on timeline. Expecting the saftey phase of the CEP2 trial to wrap up around the end of this quarter. Only then will the efficacy phase begain. Don't expect too much.
A fellow options-holder spoke with the CEO to get an idea of the likelihood of these being in the money in less than 6 months. She was very upfront, said the company will no longer be releasing fluff announcements. She said that she doesn't expect any Veyonda efficacy data any time soon. She did say that there will likely be some exciting pre-clinical data on the way for the other assets, but I doubt that will do anything dramatic for the SP.
IMO, the only thing which could come out of left field to save us option holders would be a licensing deal of some sort.
A buyout now would be disastrous. Even if offered a 100% premium to current SP, would be a miniscule deal and options would still be worthless.
NOX Price at posting:
12.5¢ Sentiment: None Disclosure: Held
